Epidemiology of sporadic inclusion body myositis

Current Opinion in Rheumatology

Volumn 28, Issue 6, 2016, Pages 657-660

  Molberg, Øyvind ^a,b   Dobloug, Cecilie ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Epidemiology; Idiopathic inflammatory myopathies; Inclusion body myositis; Population based studies; Prevalence

Indexed keywords

HUMAN; INCLUSION BODY MYOSITIS; NORWAY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; TIME TO TREATMENT; DELAYED DIAGNOSIS; EUROPE; MYOSITIS, INCLUSION BODY; RETROSPECTIVE STUDY; SJOGREN'S SYNDROME;

DELAYED DIAGNOSIS; EUROPE; HUMANS; MYOSITIS, INCLUSION BODY; PREVALENCE; RETROSPECTIVE STUDIES; SJOGREN'S SYNDROME;

EID: 84983036862     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000327     Document Type: Review

References (29)

1. Mastaglia FL, Needham M. Inclusion body myositis: a review of clinical and genetic aspects, diagnostic criteria and therapeutic approaches. J Clin Neurosci 2015; 22:6-13.
2. Benveniste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain 2011; 134:3176-3184.
3. Paltiel AD, Ingvarsson E, Lee DK, et al. Demographic and clinical features of inclusion body myositis in North America. Muscle Nerve 2015; 52:527-533.
4. Brady S, Squier W, Hilton-Jones D. Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features. J Neurol Neurosurg Psychiatry 2013; 84:1240-1246.
5. Benveniste O, Stenzel W, Hilton-Jones D, et al. Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken. Acta Neuropathol 2015; 129:611-624.
6. Lahouti AH, Amato AA, Christopher-Stine L. Inclusion body myositis: update. Curr Opin Rheumatol 2014; 26:690-696.
7. Askanas V, Engel WK, Nogalska A. Sporadic inclusion-body myositis: a degenerative muscle disease associated with aging, impaired muscle protein homeostasis and abnormal mitophagy. Biochim Biophys Acta 2015; 1852:633-643.
8. Gang Q, Bettencourt C, Houlden H, et al. Genetic advances in sporadic inclusion body myositis. Curr Opin Rheumatol 2015; 27:586-594.
9. Herbert MK, Stammen-Vogelzangs J, Verbeek MM, et al. Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann Rheum Dis 2016; 75:696-701.
10. Greenberg SA, Pinkus JL, Amato AA, et al. Association of inclusion body myositis with T cell large granular lymphocytic leukaemia. Brain 2016; 139:1348-1360.
11. Morrow JM, Sinclair CD, Fischmann A, et al. MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study. Lancet Neurol 2016; 15:65-77.
12. Lloyd TE, Mammen AL, Amato AA, et al. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology 2014; 83:426-433.
13. Ahmed M, Machado PM, Miller A, et al. Targeting protein homeostasis in sporadic inclusion body myositis. Sci Transl Med 2016; 8:331ra41.
14. Amato AA, Sivakumar K, Goyal N, et al. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology 2014; 83:2239-2246.
15. Rose MR. 188th ENMC International Workshop: Inclusion Body Myositis, 2-4 December 2011, Naarden, The Netherlands. Neuromuscular Disord 2013; 23:1044-1055.
16. Hilton-Jones D, Brady S. Diagnostic criteria for inclusion body myositis. J Intern Med 2016; 280:52-62.
17. Oflazer PS, Deymeer F, Parman Y. Sporadic-inclusion body myositis (s-IBM) is not so prevalent in Istanbul/Turkey: a muscle biopsy based survey. Acta Myol 2011; 30:34-36.
18. Badrising UA, Maat-Schieman M, van Duinen SG, et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology 2000; 55:1385-1387.
19. Verschuuren JJ, Badrising UA, Wintzen AR, et al. Inclusion body myositis. In: Emery A, editor. Diagnostic criteria for neuromuscular disorders. London, UK: Royal Society of Medicine Press; 1997. pp. 81-84.
20. Needham M, Corbett A, Day T, et al. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J Clin Neurosci V 15 2008; 1350-1353.
21. Tan JA, Roberts-Thomson PJ, Blumbergs P, et al. Incidence and prevalence of idiopathic inflammatory myopathies in South Australia: a 30-year epidemio-logic study of histology-proven cases. Int J Rheum Dis 2013; 16:331-338.
22. Wilson FC, Ytterberg SR, St Sauver JL, Reed AM. Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota. J Rheumatol 2008; 35:445-447.
23. Suzuki N, Aoki M, Mori-Yoshimura M, et al. Increase in number of sporadic inclusion body myositis (sIBM) in Japan. J Neurol 2012; 259:554-556.
24. Dobloug GC, Antal EA, Sveberg L, et al. High prevalence of inclusion body myositis in Norway; a population-based clinical epidemiology study. Eur J Neurol 2015; 22:672-741.
25. Dobloug GC, Garen T, Brunborg C, et al. Survival and cancer risk in an unselected and complete Norwegian idiopathic inflammatory myopathy cohort. Semin Arthritis Rheum 2015; 45:301-308.
26. Dobloug C, Garen T, Bitter H, et al. Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort. Ann Rheum Dis 2015; 74:1551-1556.
27. Deenen JC, van Doorn PA, Faber CG, et al. The epidemiology of neuromuscular disorders: age at onset and gender in the Netherlands. Neuromuscul Disord 2016; 7:447-452.
28. Badrising UA, Schreuder GM, Giphart MJ, et al. Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis. Neurology 2004; 63:2396-2398.
29. Rojana-udomsart A, Needham M, Luo YB, et al. The association of sporadic inclusion body myositis andSjogren's syndromeincarriersofHLA-DR3 and the 8.1 MHC ancestral haplotype. Clin Neurol Neurosurg 2011; 113:559-563.